Conditions: Stable Angina
Keywords: Major Adverse Cardiovascular Event MACE Death MI CK MB greater 3x Normal Urgent Revascularization Stent Thrombosis Bleeding
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 36
Healthy volunteers: no

Brief summary:
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).

Detailed description:
This is the first US based randomized double blinded prospective study using triple antiplatelet therapy and double dose plavix maintenance dose in aspirin resistant patients undergoing elective PCI through femoral access. The primary outcome of this study is an elevation of cardiac enzymes within 24 hours after the PCI with a secondary outcome of a composite of major adverse cardiac events of death, MI, stent thrombosis and urgent revascularization and bleeding up to 30 days.

Arms:
arm 1: Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure arm 2: Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally

Interventions: intervention 1: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel intervention 2: Antiplatelet Therapy (ASA, Clopidogrel)
Intervention descriptions: intervention 1: IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally intervention 2: Standard antiplatelet PCI treatment

Protocol document: